New Pooled Stem Cell Therapy Achieves 96% Survival Rate in High-Risk Leukemia Clinical Trial

Fred Hutch researchers report 96% survival in leukemia patients using pooled cord blood stem cells. Learn how dilanubicel is changing transplant outcomes.

By: AXL Media

Published: Apr 28, 2026, 9:20 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Breakthrough in Multi-Donor Cellular Engineering

The landscape of hematologic oncology has shifted with the publication of Phase 2 results involving a novel stem cell product known as dilanubicel. By utilizing a technique that combines genetic material from as many as nine different human sources, clinicians at the Fred Hutchinson Cancer Center have demonstrated a significant survival milestone for patients battling aggressive blood cancers. The study, led by Dr. Filippo Milano, indicates that 27 out of 28 participants remained alive one year after receiving a transplant that integrated traditional cord blood with a proprietary pooled cell expansion. This high survival rate is coupled with the rare absence of acute or chronic graft-versus-host disease, a complication that frequently undermines the success of traditional bone marrow or stem cell procedures.

Expanding Access for Ethnically Diverse Patient Groups

One of the primary hurdles in regenerative medicine has been the requirement for stringent donor matching, which often leaves multiethnic patients without viable options. Umbilical cord blood offers a natural solution due to its lower matching requirements, yet a single unit often lacks the cell volume necessary for an adult patient. The research presented in the Journal of Clinical Oncology addresses this deficit by supplementing a standard cord blood unit with dilanubicel, which is derived from six to eight different donor units. According to Dr. Milano, the Director of the Cord Blood Program at Fred Hutch, this method provides a critical bridge for those who lack a close relative or a perfectly matched unrelated donor.

The Functional Mechanics of Transient Immune Support

While the idea of introducing cells from multiple donors might suggest a risk of systemic rejection, the trial proved that the pooled product functions as a temporary biological scaffolding. Dilanubicel does not engraft for the long term, but it provides essential immune reinforcement during the vulnerable days immediately following the transplant. Laboratory observations confirmed that patients showed a rapid recovery of blood counts driven by the pooled product as early as seven days post-infusion. This early-stage support allows the primary, matched cord blood unit to establish a permanent, healthy immune system without the typical delays that often lead to life-threatenin...